Amylyx Pharmaceuticals, Inc.
AMLX
Rang în acțiuni
#4438
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical... Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
Preț acțiune
$28.26
Capitalizare de piață
$3.55B
Schimbare (1 zi)
3.41%
Schimbare (1 an)
83.88%
Țară
US
Tranzacționează Amylyx Pharmaceuticals, Inc. (AMLX)
Categorie
Healthcare
Raport P/B pentru Amylyx Pharmaceuticals, Inc. (AMLX)
Raport P/B la data de October 2026 TTM: 12.57
Conform celor mai recente rapoarte financiare și prețului acțiunilor Amylyx Pharmaceuticals, Inc., raportul P/B actual (TTM) este 12.57. La sfârșitul anului 2023, compania avea un P/B de 2.28.
Istoricul raportului P/B pentru Amylyx Pharmaceuticals, Inc. din 2019 până în 2026
Raport P/B la sfârșitul fiecărui an
| An | Raport P/B | Schimbă |
|---|---|---|
| 2026 (TTM) | 12.57 | 705.59% |
| 2024 | 1.56 | -31.54% |
| 2023 | 2.28 | -68.35% |
| 2022 | 7.22 | -204.32% |
| 2021 | -6.92 | -54.77% |
| 2020 | -15.29 | -62.00% |
| 2019 | -40.24 | 0.00% |
Raport P/B pentru companii similare sau competitoare
| Companie | Raport P/B | Diferență raport P/B | Țara |
|---|---|---|---|
| 6.251 | -50.26% |
US
|
|
| 13.2547 | 5.47% |
US
|
|
| 4.208 | -66.52% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -50.81% |
NL
|
